| 84.37 -2.4 (-2.77%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 105.18 |
1-year : | 109.68 |
| Resists | First : | 90.05 |
Second : | 93.91 |
| Pivot price | 89.2 |
|||
| Supports | First : | 83.8 |
Second : | 69.72 |
| MAs | MA(5) : | 86.78 |
MA(20) : | 89.68 |
| MA(100) : | 87.08  |
MA(250) : | 83.73 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 12 |
| RSI | RSI(14): 31.2 |
|||
| 52-week | High : | 96.29 | Low : | 72.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EW ] has closed below the lower bollinger band by 9.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ EW ] is to continue within current trading range. Bollinger Bands are 2.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 87.87 - 88.29 | 88.29 - 88.71 |
| Low: | 82.58 - 83.1 | 83.1 - 83.62 |
| Close: | 83.4 - 84.23 | 84.23 - 85.05 |
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Sat, 12 Sep 2026
Allworth Financial LP Lowers Position in Edwards Lifesciences Corporation $EW - MarketBeat
Fri, 11 Sep 2026
Insider Daniel Lippis Sells 619 Shares of Edwards Lifesciences C - GuruFocus
Fri, 11 Sep 2026
Why Edwards Lifesciences (EW) Stock Is Down Today - Quiver Quantitative
Thu, 10 Sep 2026
Edwards Lifesciences Comments on TAVR National Coverage Decision - Business Wire
Wed, 09 Sep 2026
Is Edwards Lifesciences (EW) Above Fair Value Despite Fair Cash Flow? - simplywall.st
Wed, 09 Sep 2026
Amundi Decreases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 576 (M) |
| Shares Float | 575 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 96 (%) |
| Shares Short | 10,240 (K) |
| Shares Short P.Month | 11,350 (K) |
| EPS | 1.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.42 |
| Profit Margin | 15.4 % |
| Operating Margin | 29.8 % |
| Return on Assets (ttm) | 8.3 % |
| Return on Equity (ttm) | 9.1 % |
| Qtrly Rev. Growth | 13.6 % |
| Gross Profit (p.s.) | 8.79 |
| Sales Per Share | 11.29 |
| EBITDA (p.s.) | 3.46 |
| Qtrly Earnings Growth | -25.4 % |
| Operating Cash Flow | 1,720 (M) |
| Levered Free Cash Flow | 1,230 (M) |
| PE Ratio | 50.22 |
| PEG Ratio | 1.9 |
| Price to Book value | 4.58 |
| Price to Sales | 7.47 |
| Price to Cash Flow | 28.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|